

1 **IL-1 Mediates Tissue Specific Inflammation and Severe Respiratory Failure In**  
2 **Covid-19: Clinical And Experimental Evidence**

3

4 **Running heading: IL-1 bioactivity in COVID-19**

5

6 **Georgios Renieris<sup>1</sup>, Eleni Karakike<sup>1</sup>, Theologia Gkavogianni<sup>1</sup>, Dionysia- Eirini**  
7 **Droggiti<sup>1</sup>, Dionysios Kafousopoulos<sup>1</sup>, Mihai G. Netea<sup>2,3</sup>, Jesper Eugen-Olsen<sup>4</sup>,**  
8 **John Simard<sup>5</sup>, Evangelos J. Giamarellos-Bourboulis<sup>1</sup>**

9

10 **<sup>1</sup> 4<sup>th</sup> Department of Internal Medicine, National and Kapodistrian University of**  
11 **Athens, Medical School, 124 62 Athens, Greece**

12 **<sup>2</sup>Immunology and Metabolism, Life & Medical Sciences Institute, University of**  
13 **Bonn, 53115 Bonn, Germany**

14 **<sup>3</sup>Department of Internal Medicine and Center for Infectious Diseases, Radboud**  
15 **University, 6500 Nijmegen, the Netherlands**

16 **<sup>4</sup>Department of Clinical Research, Copenhagen University Hospital Hvidovre,**  
17 **2650 Hvidovre, Denmark**

18 **<sup>5</sup>XBiotech, 78744 Austin, Texas, USA**

19

20 **Correspondence**

21 E. J. Giamarellos-Bourboulis, MD, PhD

22 4<sup>th</sup> Department of Internal Medicine, ATTIKON University General Hospital

23 1 Rimini Street 124 62, Athens, Greece

24 Tel: +30 210 58 31 994/ Fax: +30 210 53 26 446

25 E-mail: [egiamarel@med.uoa.gr](mailto:egiamarel@med.uoa.gr)

26 **ABSTRACT**

27 **Background:** Acute respiratory distress syndrome (ARDS) in COVID-19 has been  
28 associated with dysregulated immune responses leading to catastrophic  
29 inflammation. The activation pathways remain to be fully elucidated. We investigated  
30 the ability of circulating to induce dysregulated immune responses.

31 **Materials & Methods:** Calprotectin and high mobility group box 1 (HMGB1) were  
32 associated with ARDS in 60 COVID-19 patients. In a second cohort of 40 COVID-19  
33 patients calprotectin at hospital admission was associated with serum levels of  
34 soluble urokinase plasminogen activator receptor (suPAR). A COVID-19 animal  
35 model was developed by intravenous injection of plasma from healthy volunteers or  
36 patients with COVID-19 ARDS into C57/BL6 mice once daily for 3 consecutive days.  
37 In separate experiments, mice were treated with a) the IL-1 receptor antagonist  
38 Anakinra or vehicle and b) Flo1-2a anti-murine anti-IL-1 $\alpha$  monoclonal antibody or the  
39 specific anti-human IL-1 $\alpha$  antibody XB2001, or isotype controls. Mice were sacrificed  
40 on day 4. Cytokines and myeloperoxidase (MPO) in tissues were measured.

41 **Results:** Calprotectin, but not HMGB1, was elevated ARDS. Higher suPAR readouts  
42 indicated higher calprotectin levels. Challenge of mice with COVID-19 plasma led to  
43 inflammatory reactions in murine lung and intestines as evidenced by increased  
44 levels of TNF $\alpha$ , IL-6, IFN $\gamma$  and MPO. Anakinra treatment brought these levels down.  
45 Similar decrease was found in mice treated with Flo1-2a but not with XB2001.

46 **Conclusion:** Circulating alarmins, specifically calprotectin, of critically ill COVID-19  
47 patients induces tissue-specific inflammatory responses through an IL-1 $\alpha$  mediated  
48 mechanism. This could be attenuated through inhibition of IL-1 receptor or specific  
49 inhibition of IL-1 $\alpha$ .

50 **Keywords:** calprotectin, tumor necrosis factor, interleukin-6, interleukin-1 $\alpha$ , suPAR,

51 acute respiratory distress syndrome (ARDS), severe respiratory failure, COVID-19

52

## 53 INTRODUCTION

54 A little over one year since the onset of the COVID-19 pandemic, more than  
55 2.3 million deaths have been attributed to the virus  
56 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>). Despite all  
57 efforts to understand the disease, efforts are ongoing to elucidate what drives  
58 progression in COVID-19 cases from lower respiratory tract infections (LRTI) to  
59 acute respiratory distress syndrome (ARDS). We have suggested that the  
60 deterioration from pneumonia to ARDS is the result of a complex immune  
61 dysregulation, which in about 25% of patients appears to be related to a macrophage  
62 activation like syndrome; while in the remaining 75% of patients the mechanism  
63 seems to involve an interleukin (IL)-6 receptor dependent dysregulation, with an  
64 associated lymphopenia and a subset of cytokine over-producing monocytes that  
65 show decreased human leukocyte antigen (HLA)-DR expression (1).

66 Recent data suggests that SARS-CoV-2 stimulates vicious pro-inflammatory  
67 responses inducing NLRP3 inflammasome activation in monocytes and  
68 macrophages (2). In the open-label phase II study SAVE (3), patients with LRTI  
69 caused by SARS-CoV-2 and showing plasma concentrations of the biomarker  
70 suPAR (soluble urokinase plasminogen activator receptor)  $\geq 6$  ng/ml were treated  
71 with the recombinant human IL-1 receptor antagonist Anakinra. Anakinra is able to  
72 block both IL-1 $\alpha$  and IL-1 $\beta$  bioactivity at the level of their common receptor (4) and  
73 prevent the development of ARDS.

74 The results of the SAVE trial led us to hypothesise that LRTI caused by  
75 SARS-CoV-2 can progress to ARDS. In this hypothesis, as a result of infection by  
76 SARS-CoV-2, patients over-produce IL-1 $\alpha$  and other danger-associated molecular  
77 patterns (DAMPs) from their lung parenchyma. DAMPs trigger the release of IL-1 $\beta$

78 and in combination with IL-1 $\alpha$  evoke strong innate immune pro-inflammatory  
79 responses which lead to ARDS (1). In order to test our hypothesis, we used a three-  
80 step approach. In the first step, we measured and found higher concentrations of the  
81 DAMP calprotectin in the plasma of patients with ARDS than patients without ARDS.  
82 In the second step, we measured and found that DAMP concentrations in the plasma  
83 of patients with suPAR more than 6 ng/ml were significantly higher than that in  
84 patients with suPAR less than 6 ng/ml. In the third step, we studied a COVID-19-like  
85 animal model, where we prevented the development of strong pro-inflammatory  
86 responses through inhibition of IL-1 signalling via Anakinra or anti-IL-1 $\alpha$  antibodies.

87

88

## 89 **PATIENTS & METHODS**

### 90 **Clinical study**

91 Plasma samples from a cohort of 60 patients with and without ARDS that was  
92 determined to be caused by SARS-CoV (approval 30/20 by the National Ethics  
93 Committee of Greece; approval IS 021-20 by the National Organization for  
94 Medicines of Greece) and from 40 participants in the SAVE trial (suPAR-guided  
95 Anakinra treatment for Validation of the risk and Early management of severe  
96 respiratory failure by COVID-19; EudraCT number 2020-001466-11; National Ethics  
97 Committee approval 38/20; National Organization for Medicines approval ISO 28/20;  
98 ClinicalTrials.gov registration NCT04357366) were analyzed.

99 Patients were enrolled after written informed consent was provided by  
100 themselves or by first-degree relatives in case of patients unable to consent. All  
101 patients were adults of either sex with positive molecular testing of SARS-CoV-2  
102 from respiratory secretions and with LRTI defined by the presence of diffuse

103 infiltrates by chest X-ray or computed tomography of the chest. Exclusion criteria  
104 were a) HIV-1 infection and b) neutropenia defined as less than 1,000  
105 neutrophils/mm<sup>3</sup>. Blood was sampled on the day of hospital admission in the  
106 emergencies. For patients admitted with ARDS, blood was collected within 24 hours  
107 from mechanical ventilation (MV). Control blood samples were collected from healthy  
108 volunteers matched for age and gender.

109 The following clinical variables were recorded: i) demographics; ii) severity  
110 scores, namely Acute Physiology and Chronic Health Evaluation (APACHE) II score,  
111 Charlson's Comorbidity Index (CCI) and Sequential Organ Failure Assessment  
112 (SOFA) score; (iii) absolute blood cell counts, biochemistry, and blood gases; (iv)  
113 and progression into ARDS during the entire hospital stay. ARDS was defined as a  
114 ratio of partial oxygen pressure to fraction of inspired oxygen ( $PaO_2 / FiO_2$ ) below  
115 150 mmHg necessitating mechanical ventilation.

116 Five millilitres of whole blood was collected into a tube containing  
117 ethylenediaminetetraacetic acid (EDTA) and centrifuged. Calprotectin (S100A8/A9);  
118 high-mobility group box 1 (HMGB1); suPAR and ferritin were measured by enzyme-  
119 linked immunosorbent assays (ELISA) (InflaRx, Jena, Germany and Creative  
120 Diagnostics, Shirley, NY, USA; suPARnostic, ViroGates, Lyngby, Denmark and  
121 ORGENTEC Diagnostika GmbH, Mainz, Germany, respectively); and C-reactive  
122 protein (CRP) was measured using a nephelometric assay (Behring, Berlin,  
123 Germany). The lowest limits of detection were: 0.5 ng/ml for HMGB1; 1.1 ng/ml for  
124 suPAR; 0.2 mg/l for CRP; and 75 ng/ml for ferritin. RNA isolation of SARS-CoV-  
125 2 was performed with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany).  
126 Reverse transcription of the viral RNA into cDNA and enrichment of the sequences  
127 of interest via Real-time Polymerase Chain Reaction (PCR) was performed in the

128 Rotor-Gene Q instrument (Qiagen) using the SARS-CoV-2 reagent Viasure (CerTest  
129 Biotec SL, Zaragoza, Spain).

130

### 131 **Animal model of COVID-19 Pathogenic Inflammation**

132 Animal experiments were conducted in the Unit of Animals for Medical and  
133 Scientific purposes of the University General Hospital “Attikon” (Athens, Greece). All  
134 experiments were licensed from the Greek veterinary directorate under the protocol  
135 number 471955/06-07-2020.

136 We studied 80 male and female C57Bl6 mice (7-8 weeks old). Mice were  
137 allowed to acclimate for seven days before beginning of the experiments. They were  
138 housed in typical mouse cages, up to 5 mice per cage on 12-h dark/light cycle and  
139 allowed free access to standard dry rodent diet and water. Analgesia was achieved  
140 with paracetamol suppositories to avoid interactions with the immune system.

141 In order to develop a model of COVID-19-like inflammatory illness, mice were  
142 treated intravenously (iv) with 100 µl of plasma from patients with ARDS due to  
143 SARS-CoV-2 infection for 3 consecutive days; control mice were treated with 100 µl  
144 of plasma from healthy volunteers for 3 consecutive days. On the fourth day, mice  
145 were sacrificed by subcutaneous (sc) injection of 300 mg/kg ketamine, followed by  
146 cervical dislocation. Under sterile conditions a midline abdominal incision was  
147 performed. Then, segments of liver, lower lobe of the right lung, right kidney, ileum  
148 (ca. 1 cm distally to the pyloric sphincter) and colon (ca. 1 cm proximally of the anal  
149 ring) were excised and collected into sterile tubes with 1 ml NaCl 0.9%. The  
150 intestinal samples were thoroughly flushed with NaCl 0.9% for removal of feces  
151 before storage. The samples were weighed and homogenized.

152 Segments of spleens were gently squeezed and passed through a sterile filter  
153 (250 mm, 12-13 cm, AlterChem Co, Athens, Greece) for the collection of  
154 splenocytes. Peritoneal cells were retrieved by peritoneal lavage with 10 ml of cold  
155 PBS containing 2 mmol/l of EDTA. After three serial washings, spleencells and  
156 peritoneal cells were counted on Neubauer plates with trypan blue for exclusion of  
157 dead cells. A total of  $5 \times 10^6$  cells/ml were incubated in sterile 24-well plates in  
158 RPMI-1640, supplemented with 2 mM glutamine, 10% fetal bovine serum, 100 U/ml  
159 of penicillin G and 0.1 mg/ml of streptomycin, in the absence or presence of 10 ng/ml  
160 lipopolysaccharide (LPS) of *Escherichia coli* O55:B5 or  $5 \times 10^5$  cfu/ml heat killed  
161 *Candida albicans* (HKCA). After 24 hours or 5 days of incubation at 37°C in 5% CO<sub>2</sub>,  
162 the plates were centrifuged, and the supernatants were collected. Concentrations of  
163 tumor necrosis factor alpha (TNF $\alpha$ ), interferon gamma (IFN $\gamma$ ) and IL-6, IL-17A and  
164 IL-22 in supernatants from tissue samples and spleencells were measured in  
165 duplicate by an enzyme immunosorbent assay (ThermoFisher Scientific,  
166 Massachussets, USA) according to the manufacturer's instructions. The lowest  
167 detections limits were as follows: for TNF $\alpha$  19 pg/ml; for IFN $\gamma$  16 pg/ml; for IL-6 10  
168 pg/ml; for IL-17A 8 pg/ml; and for IL-22 16 pg/ml.

169 Myeloperoxidase (MPO) activity in all collected tissues was determined.  
170 Tissue segments were homogenized with T-PER® (ThermoFisher Scientific) and  
171 centrifuged at 10,000 rpm at 4°C. Then the homogenates were incubated in wells of  
172 a 96-well plate at 37°C with 4.2 mM tetramethylbenzidine (Serva, Heidelberg,  
173 Germany), 2.5 mM citrate, 5 mM NaH<sub>2</sub>PO<sub>4</sub> and 1.18 mM H<sub>2</sub>O<sub>2</sub> pH 5.0 at a final  
174 volume of 150  $\mu$ l. After 5 minutes the reaction was terminated by adding 50 ml 0.18  
175 M H<sub>2</sub>SO<sub>4</sub>. Absorbance was read at 450 nm against blank wells. Results were  
176 adjusted for tissue sample protein content on Bradford assay (Sigma-Aldrich) and



177 they were expressed as MPO units/mg protein/g.

178 Experiments were repeated in mice receiving in addition to i.v. plasma, a) 100  
179  $\mu$ l sc of 10 mg/kg Anakinra (Swedish Orphan Biovitrum, Stockholm, Sweden) or 100  
180  $\mu$ l of 0.9% NaCl once daily for 3 days; and b) 100  $\mu$ l intraperitoneally (ip) of 1000  
181  $\mu$ g/ml (12) anti-murine IL-1 $\alpha$  antibody Flo1-2a or human IL- 1 $\alpha$  antibody XB2001, or  
182 murine isotype control (XBiotech, TX, USA).

183 In a separate experiment, mice treated with COVID-19 plasma for three days  
184 were challenged on the fourth day ip with  $1 \times 10^7$  cfu/ml *E. coli* or *Acinetobacter*  
185 *baumannii*. Survival was recorded every 12 hours for 7 days.

186

## 187 **Statistics**

188 Categorical data were presented as frequencies and quantitative variables as  
189 mean  $\pm$  SE. Comparisons between groups were done using the Fisher exact test for  
190 categorical data. Comparison for quantitative data was performed using the Mann-  
191 Whitney U test for two group comparisons and the one-way ANOVA with the  
192 Bonferroni correction for multiple group comparison. Correlations were performed  
193 using the Spearman's rank of order. Any p value below 0.05 was considered  
194 statistically significant.

195

## 196 **RESULTS**

197 Forty consecutive patients with COVID-19 who did not develop ARDS during  
198 their hospital stay and 20 consecutive patients with ARDS were analyzed. Their  
199 demographics are shown in Table 1. Samples of 10 healthy volunteers were  
200 analyzed as healthy controls. Serum calprotectin levels were significantly higher  
201 among patients with COVID-19 and ARDS (Figure 1A). HMGB1 concentrations did

202 not differ between patients with COVID-19 with and without ARDS (Figure 1B).  
203 Elevated calprotectin levels COVID-19-related ARDS raised the question whether  
204 calprotectin is released early among patients and may serve as a marker for patients  
205 who will progress to ARDS.

206 suPAR was previously identified as an early predictor of ARDS progression in  
207 patients with at least 6 ng/ml serum levels in the SAVE trial (3). To study of the early  
208 increase of suPAR denotes increases of calprotectin, calprotectin was measured in  
209 40 patients screened for inclusion in SAVE trial. 20 patients were with suPAR  
210 concentrations less than 6 ng/ml and 20 patients showed suPAR concentrations  $\geq$  6  
211 ng/ml (Table 2). None of the patients with suPAR less than 6 ng/ml developed ARDS;  
212 30% of those with suPAR  $\geq$  6 ng/ml progressed into ARDS. Remarkably, patients with  
213 suPAR concentrations  $\geq$  6 ng/ml had significantly higher concentrations of  
214 calprotectin (Figure 1C). A significant positive correlation between calprotectin and  
215 suPAR was thus demonstrated (Figure 1D). These findings demonstrated that both  
216 suPAR and calprotectin are reliable prognostic biomarkers in predicting the  
217 development of severe respiratory failure in COVID-19. These findings also  
218 suggested that DAMPs like calprotectin, released at early stages of clinical infection  
219 are involved in mediating the progression of pneumonia into ARDS.

220 In order to investigate the mechanism by which calprotectin induces the  
221 hyperinflammation related to COVID-19 associated respiratory failure, we sought to  
222 design a COVID-19 murine model. Mice were challenged with plasma either from  
223 healthy volunteers (HV) or from patients with ARDS of COVID-19. Plasma of COVID-  
224 19 patients led to organ-specific increase of cytokine concentrations. More precisely,  
225 TNF $\alpha$  and MPO activity were specifically increased in the lung, ileum and colon of  
226 mice challenged with COVID-19 plasma; IL-6 was upregulated in the lung and colon;

227 and IFN $\gamma$  was upregulated in the lung (Figure 2A to D). These findings demonstrated  
228 a compartmentalized inflammatory response in mice after challenging with COVID-  
229 19 patient plasma.

230 DAMPs, like calprotectin, act on monocytes and macrophages and tend to  
231 stimulate intense IL-1 responses. To provide evidence on the contribution of IL-1  
232 stimulation, mice challenged with plasma from HV or COVID-19 patients were  
233 treated with N/S or with Anakinra; the latter blocks both human and murine IL-1 $\alpha$  and  
234 IL-1 $\beta$ . Treatment with Anakinra significantly reduced tissue concentrations of TNF $\alpha$ ,  
235 IL-6, IFN- $\gamma$  and MPO activity (Figure 3A to 3I). However, the observed inflammation  
236 may have been mediated through human IL-1 $\alpha$  present in the plasma of COVID-19  
237 patients. To further clarify this, mice challenged with COVID-19 plasma were treated  
238 with the anti-murine specific anti-IL-1 $\alpha$  antibody Flo1-2a and with the human specific  
239 anti-human IL-1 $\alpha$  antibody XB2001, respectively. Treatment with Flo1-2a  
240 significantly reduced tissue concentrations of TNF $\alpha$ , IL-6, IFN $\gamma$  and MPO activity in  
241 contrast to treatment with XB2001 (Figure 4A to 4I). This suggests that the host-  
242 derived mouse IL-1 $\alpha$  and not any injected human IL-1 $\alpha$  was necessary to induce the  
243 compartmentalized inflammation.

244 Treatment with Anakinra led to an increase in ex vivo production capacity of  
245 IFN $\gamma$  and TNF $\alpha$ , but not of IL-6, IL-17A or IL-22 from splenocytes following  
246 stimulation with HKCA (Figure 5A to 5F and Figure S1A to S1D). HKCA targets  
247 lymphocyte responses from splenocytes and the cytokine responses are compatible  
248 with increase of Th1 responses following treatment with Anakinra.

249 The number of transcripts of core SARS-CoV-2 genes *ORF1ab* and *N* were  
250 indirectly provided by the cycles (Ct) of PCR positivity in plasma samples that were  
251 used for the induction of the COVID-19-like hyperinflammation in the murine model.

252 No correlation was found between Cts and the levels of TNF $\alpha$ , IL-6, IFN $\gamma$  and MPO in  
253 the lung of COVID-19 patients with ARDS due to COVID-19 (Figure S2). This suggests  
254 that the hyperinflammation is independent from the viral load. In order to mimic hospital  
255 acquired secondary bacterial infections among COVID-19 patients in murine, mice  
256 treated for three consecutive days with COVID-19 plasma were further challenged  
257 with *A. baumannii* or *E. coli*. Survival was significantly lower after challenging with *A.*  
258 *baumannii* (Figure 3E). Observations coming from our prospective cohort of 134  
259 ARDS patients revealed higher incidence of secondary infections by *A. baumannii*  
260 when compared to other Gram-negative bacteria (Table S1, Figure S3). This further  
261 supports the immunological similarities of the developed animal model to the human  
262 infection.

263

## 264 **DISCUSSION**

265 This study presented evidence that severe respiratory failure in COVID-19  
266 patients is possibly triggered by DAMPs, most likely calprotectin, which are released  
267 early after the interaction of SARS-CoV-2 with host cells. It may well be the case that  
268 calprotectin is this specific DAMP since circulating levels of HMGB1, another DAMP,  
269 do not follow those of calprotectin. DAMPs lead to a compartmentalized inflammation  
270 through enhancement of the production of pro-inflammatory cytokines IL-1 $\alpha$  and IL-  
271 1 $\beta$ .

272 It has been clearly demonstrated that an impaired immune response is a core  
273 characteristic of patients who develop ARDS due to SARS-CoV-2 (5). The  
274 associated great increase in the mortality of these patients has turned the focus on  
275 potential therapeutic targets to disrupt the immune dysregulation. This necessitates a  
276 better understanding of the pathogenesis of COVID-19.

277 Calprotectin, a heterodimer of S100A8 and S100A9, is a protein secreted by  
278 leukocytes. The upregulation of calprotectin expression has been associated with  
279 various inflammatory processes such as inflammatory bowel disease, rheumatoid  
280 arthritis, spondyloarthritis and cardiovascular disease in type 2 diabetes mellitus (6-  
281 9). Additionally, calprotectin is crucial for neutrophil accumulation and inflammation  
282 in the lung parenchyma during bacterial community acquired pneumonia (10).  
283 Recently, high levels of calprotectin in samples of COVID-19 patients were  
284 correlated with disease severity and were associated with increased levels of  
285 inflammatory cytokines and chemokines and myelopoiesis of abnormal myeloid cells  
286 (11). In this study, we suggest calprotectin as a potential first element in the pathway  
287 leading to ARDS in COVID-19 patients. Indeed, we found greater levels in patients  
288 with ARDS compared to patients without ARDS. On the contrary, HMGB1, an  
289 additional alarmin, which has been associated with sepsis pathogenesis and  
290 outcome (12), did not significantly differ among patients with and without ARDS due  
291 to COVID-19. Moreover, suPAR which is an early predictor of respiratory  
292 deterioration in COVID-19 (3, 13) was indicative of patients with higher calprotectin  
293 levels, suggesting that increased suPAR can be the biomarker of DAMP-induced  
294 pathways in COVID-19.

295 SARS-CoV-2 uses the cellular surface protein angiotensin-converting enzyme  
296 2 (ACE2) to bind and enter cells. However, the mouse ACE2 does not effectively  
297 bind the viral spike protein (14). Therefore wild-type mice cannot be directly used as  
298 a model to gain insight in COVID-19 pathophysiology. Mice over-expressing ACE2  
299 have been used as a strategy to tackle this problem (15). While it is accepted that  
300 the interaction of the spike protein of SARS-CoV-2 with human angiotensin  
301 converting enzyme 2 (ACE2) is the first step for viral invasion in host cells of the

302 upper and lower respiratory tract (16), the ability of the virus to directly infect other  
303 human tissues, where ACE2 is also expressed, such as the small intestine, kidneys,  
304 and the heart, is a matter of dispute (17). In addition, we also need to understand the  
305 pure immunological mechanisms of hyperinflammation in COVID-19. This is  
306 introducing the need of COVID-19 models like the one developed after animal  
307 challenge with human plasma. The model simulates the inflammatory reaction in  
308 human SARS-CoV-2 infection since it provides compartmentalized  
309 hyperinflammation of the lung.

310 Calprotectin acts through the Toll like receptor 4 (TLR4) and the receptor for  
311 advanced glycation end-products (RAGE) and may prime for intracellular pro-IL-1 $\beta$   
312 (18) which is subsequently cleaved by SARS-CoV-2 activated NLRP3 inflammasome  
313 (2) into IL-1 $\beta$ . Anakinra prevents the inflammatory action of both IL-1 $\alpha$  and IL-1 $\beta$  by  
314 blocking their cellular receptor. IL-1 $\alpha$  released during cell death is characterized by  
315 an autocrine function enabling an amplifying loop of inflammation (19). Moreover, we  
316 have shown that Anakinra enhances the Th1 response in mice and probably  
317 improves viral clearance.

318 Our findings provide evidence that progression from LRTI by SARS-CoV-2 to  
319 ARDS is a process which is mediated by DAMPs, like IL-1 $\alpha$  and calprotectin,  
320 released following cell destruction. The early detection of the presence of circulating  
321 DAMPs and blockade through IL-1a inhibition may represent a viable therapeutic  
322 strategy. This is the hallmark of the efficacy of Anakinra - guided by the biomarker  
323 suPAR - which led to a significant decrease in the incidence of ARDS in the SAVE  
324 trial (3).

325

326

327 **Acknowledgments**

328 We thank Zhongli Xu, Katja Schubert, Marlen Hermann (InflaRx GmbH, Jena,  
329 Germany) for the measurements of calprotectin in patient samples as well as for  
330 their critical review of the manuscript.

331

332 **Competing interests**

333 J. Eugen-Olsen is a cofounder, shareholder and CSO of ViroGates A7S, Denmark  
334 and is named inventor on patents on suPAR owned by Copenhagen University  
335 Hospital Hvidovre, Denmark. He is granted by the Horizon 2020 European Grant  
336 RISKinCOVID.

337 J. Simard is the CEO and founder of XBiotech.

338 M.G. Netea is a scientific founder of TTxD, and received research grants from GSK  
339 and ViiV Healthcare.

340 E.J. Giamarellos-Bourboulis has received honoraria from AbbVie USA, Abbott CH,  
341 InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent  
342 educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield,  
343 bioMérieux Inc, InflaRx GmbH, and XBiotech Inc.; and funding from the FrameWork  
344 7 program HemoSpec (granted to the National and Kapodistrian University of  
345 Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted  
346 to the National and Kapodistrian University of Athens), and the Horizon 2020  
347 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of  
348 Sepsis).

349

350 **Funding**

351 The study was funded in part by the Hellenic Institute for the Study of Sepsis and in  
352 part by the Horizon 2020 grant RISKinCOVID. The funders had no role in the design,  
353 collection, analysis and interpretation of data, writing, and decision to publish.

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375



376 **REFERENCES**

- 377 1. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,  
378 Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, Ntaganou  
379 M, Kyriakopoulou M, Dimopoulos G, Koutsodimitropoulos I, Velissaris D,  
380 Koufargyris P, Karageorgos A, Katrini K, Lekakis V, Lupse M, Kotsaki A, Renieris  
381 G, Theodoulou D, Panou V, Koukaki E, Koulouris N, Gogos C, Koutsoukou A.  
382 Complex immune dysregulation in COVID-19 patients with severe respiratory  
383 failure. *Cell Host Microbe*. 2020;27:992-1000.e3.
- 384 2. Rodrigues TS, de Sá KSG, Ishimoto AY, Becerra A, Oliveira S, Almeida L,  
385 Gonçalves AV, Perucello DB, Andrade WA, Castro R, Veras FP, Toller-Kawahisa  
386 JE, Nascimento DC, de Lima MHF, Silva CMS, Caetite DB, Martins RB, Castro  
387 IA, Pontelli MC, de Barros FC, do Amaral NB, Giannini MC, Bonjorno LP, Lopes  
388 MIF, Santana RC, Vilar FC, Auxiliadora-Martins M, Luppino-Assad R, de Almeida  
389 SCL, de Oliveira FR, Batah SS, Siyuan L, Benatti MN, Cunha TM, Alves-Filho  
390 JC, Cunha FQ, Cunha LD, Frantz FG, Kohlsdorf T, Fabro AT, Arruda E, de  
391 Oliveira RDR, Louzada-Junior P, Zamboni DS. Inflammasomes are activated in  
392 response to SARS-CoV-2 infection and are associated with COVID-19 severity in  
393 patients. *J Exp Med*. 2021;218:e20201707.
- 394 3. Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G,  
395 Gatselis N, Karakike E, Saridaki M, Loli G, Stefos A, Prasianaki D, Georgiadou S,  
396 Tsachouridou O, Petrakis V, Tsiakos K, Kosmidou M, Lygoura V, Dareioti M,  
397 Milionis C, Papanikolaou IC, Akinosoglou K, Myrodi DM, Gravvani A, Stamou A,  
398 Gkavogianni T, Katrini K, Marantos T, Trontzas IP, Syrigos K, Chatzis L, Chatzis  
399 S, Vechlidis N, Avgoustou C, Chalvatzis S, Kyprianou M, van der Meer JWM,

- 400 Eugen-Olsen J, Netea MG, Giamarellos-Bourboulis EJ. An open label trial of  
401 Anakinra to prevent respiratory failure in COVID-19. *eLife*. 2021;10:e66125.
- 402 4. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS,  
403 Begun J, Plantinga TS, Joosten LA, van der Meer JW, Chamilos G, Netea MG,  
404 Xavier RJ, Dinarello CA, Romani L, van de Veerdonk FL. IL-1 receptor blockade  
405 restores autophagy and reduces inflammation in chronic granulomatous disease  
406 in mice and in humans. *Proc Natl Acad Sci*. 2014;111:3526–31.
- 407 5. Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of  
408 COVID-19: Mechanisms underlying disease severity and progression.  
409 *Physiology*. 2020;35:288-301.
- 410 6. Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H,  
411 Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T. Detection of calprotectin  
412 in inflammatory bowel disease: Fecal and serum levels and immunohistochemical  
413 localization. *Int J Mol Med*. 2018;41:107-118.
- 414 7. Azramezani Kopi T, Shahrokh S, Mirzaei S, Asadzadeh Aghdai H, Amini  
415 Kadijani A. The role of serum calprotectin as a novel biomarker in inflammatory  
416 bowel diseases: a review study. *Gastroenterol Hepatol Bed Bench*. 2019;12:183-  
417 189.
- 418 8. Jarlborg M, Courvoisier DS, Lamacchia C, Martinez Prat L, Mahler M, Bentow C,  
419 Finckh A, Gabay C, Nissen MJ; physicians of the Swiss Clinical Quality  
420 Management (SCQM) registry. Serum calprotectin: a promising biomarker in  
421 rheumatoid arthritis and axial spondyloarthritis. *Arthritis Res Ther*. 2020;22:105.
- 422 9. Oosterwijk MM, Bakker SJL, Nilsen T, Navis G, Laverman GD. Determinants of  
423 increased serum calprotectin in patients with type 2 diabetes mellitus. *Int J Mol*  
424 *Sci*. 2020;21:8075.

- 425 10. Kotsiou OS, Papagiannis D, Papadopoulou R, Gourgoulialis KI. Calprotectin in  
426 lung diseases. *Int J Mol Sci.* 2021;22:1706.
- 427 11. Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C,  
428 Hénon C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C,  
429 Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D,  
430 Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V,  
431 Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I,  
432 Barlesi F, Marabelle A, Pène F, Gachot B, André F, Zitvogel L, Ginhoux F,  
433 Fontenay M, Solary E. Elevated calprotectin and abnormal myeloid cell subsets  
434 discriminate severe from mild COVID-19. *Cell.* 2020;182:1401-1418.e18.
- 435 12. Karakike E, Adami ME, Lada M, Gkavogianni T, Koutelidakis IM, Bauer M,  
436 Giamarellos-Bourboulis EJ, Tsangaris I. Late peaks of HMGB1 and sepsis  
437 outcome: evidence for synergy with chronic inflammatory disorders. *Shock.*  
438 2019;52:334-339.
- 439 13. Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-  
440 Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an  
441 early predictor of severe respiratory failure in patients with COVID-19 pneumonia.  
442 *Crit Care.* 2020;24:187.
- 443 14. Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by  
444 novel coronavirus from Wuhan: an analysis based on decade-long structural  
445 studies of SARS coronavirus. *J Virol.* 2020;94:e00127-20.
- 446 15. Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Riveros-Balta AX,  
447 Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I,  
448 Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D,  
449 Finch CL, Frieman MB, Graham BS, Gralinski LE, Guilfoyle K, Haagmans BL,

- 450 Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra WB, Knezevic I,  
451 Krause PR, Kuhn JH, Le Grand R, Lewis MG, Liu WC, Maisonnasse P, McElroy  
452 AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B,  
453 Rodríguez E, Rogers TF, Salguero FJ, Schotsaert M, Stittelaar KJ, Thibaut HJ,  
454 Tseng CT, Vergara-Alert J, Beer M, Brasel T, Chan JFW, García-Sastre A, Neyts  
455 J, Perlman S, Reed DS, Richt JA, Roy CJ, Segalés J, Vasan SS, Henao-  
456 Restrepo AM, Barouch DH. Animal models for COVID-19. *Nature*. 2020;586:509-  
457 515.
- 458 16. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor  
459 usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol*.  
460 2020;5:562-569.
- 461 17. Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, Blecher-Gonen R, Cohen M,  
462 Medaglia C, Li H, Deczkowska A, Zhang S, Schwikowski B, Zhang Z, Amit I.  
463 Host-viral infection maps reveal signatures of severe COVID-19 patients. *Cell*.  
464 2020;181:1475-1488.e12.
- 465 18. Vogl T, Stratis A, Wixler V, Völler T, Thurainayagam S, Jorch SK, Zenker S,  
466 Dreiling A, Chakraborty D, Fröhling M, Paruzel P, Wehmeyer C, Hermann S,  
467 Papantonopoulou O, Geyer C, Loser K, Schäfers M, Ludwig S, Stoll M,  
468 Leanderson T, Schultze JL, König S, Pap T, Roth J. Autoinhibitory regulation of  
469 S100A8/S100A9 alarmin activity locally restricts sterile inflammation. *J Clin*  
470 *Invest*. 2018;128:1852-66.
- 471 19. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related  
472 cytokines in the regulation of inflammation and immunity. *Immunity*. 2019;50:778-  
473 795.
- 474  
475

**Table 1. Baseline clinical and laboratory characteristics of patients according to the development of ARDS due to pneumonia by the SARS-CoV-2 coronavirus**

	No ARDS (n=40)	ARDS (n=20)	p-value
Age (years, mean $\pm$ SD) <sup>#</sup>	57.3 $\pm$ 14.85	66.60 $\pm$ 11.45	0.020 <sup>#</sup>
Male gender (n, %)	33 (82.5)	17 (85.0)	0.559 <sup>□</sup>
CCI (mean $\pm$ SD) <sup>#</sup>	1.85 $\pm$ 1.66	3.55 $\pm$ 2.56	0.012 <sup>#</sup>
APACHE II score (mean $\pm$ SD) <sup>#</sup>	5.50 $\pm$ 3.11	10.05 $\pm$ 5.07	0.001 <sup>#</sup>
SOFA (mean $\pm$ SD) <sup>#</sup>	1.87 $\pm$ 1.66	3.35 $\pm$ 1.06	0.001 <sup>#</sup>
<b>Main comorbidities (n, %)</b>			
Type 2 diabetes mellitus	6 (15.0)	6 (30.0)	0.189 <sup>□</sup>
Congestive heart failure	1 (2.5)	2 (10.0)	0.255 <sup>□</sup>
Coronary heart disease	1 (2.5)	4 (20.0)	0.038 <sup>□</sup>
Chronic renal disease	1 (2.5)	0 (0)	0.667 <sup>□</sup>
COPD	4 (10.0)	3 (15.0)	0.676 <sup>□</sup>
<b>Laboratory values (mean <math>\pm</math> SD)</b>			
White blood cells (mm <sup>3</sup> )	6098.46 $\pm$ 2102.44	8758.00 $\pm$ 3992.08	0.003 <sup>#</sup>
Absolute neutrophil counts (mm <sup>3</sup> )	4535.52 $\pm$ 2110.35	7437.75 $\pm$ 3762.13	0.001 <sup>#</sup>
Absolute lymphocyte counts (mm <sup>3</sup> )	1065.98 $\pm$ 419.86	810.04 $\pm$ 426.46	0.025 <sup>#</sup>
Platelets (x 10 <sup>3</sup> , mm <sup>3</sup> )	191.2 $\pm$ 85.6	178.3 $\pm$ 54.9	0.389 <sup>#</sup>
C-reactive protein (mg/l)	124.55 $\pm$ 100.73	206.38 $\pm$ 85.96	0.014 <sup>#</sup>
Fibrinogen (mg/dl)	510.59 $\pm$ 172.91	611.20 $\pm$ 199.78	0.262 <sup>#</sup>
Ferritin (ng/ml)	1136.05 $\pm$ 1022.05	1288.83 $\pm$ 573.13	0.381 <sup>#</sup>
Procalcitonin (ng/ml)	0.25 $\pm$ 0.39	0.38 $\pm$ 0.46	0.280 <sup>#</sup>
D-dimers (ng/ml)	599.76 $\pm$ 364.72	763.00 $\pm$ 702.42	0.464 <sup>#</sup>
AST (U/l)	41.32 $\pm$ 26.62	64.80 $\pm$ 108.08	0.502 <sup>#</sup>
ALT (U/l)	39.33 $\pm$ 34.24	52.80 $\pm$ 74.30	0.822 <sup>#</sup>
Creatinine (mg/dl)	0.89 $\pm$ 0.18	1.29 $\pm$ 1.16	0.006 <sup>#</sup>
Total bilirubin (mg/dl)	0.59 $\pm$ 0.54	5.25 $\pm$ 18.34	0.211 <sup>#</sup>

**Abbreviations:** SD: standard deviation; APACHE: acute physiology and chronic health evaluation; CCI: Charlson's comorbidity index; SOFA: sequential organ failure; COPD: chronic obstructive pulmonary disease; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ARDS: acute respiratory distress syndrome

<sup>□</sup>Comparison by Fischer exact test; <sup>#</sup>Comparison by the Mann-Whitney U test.

476

477

**Table 2. Baseline clinical and laboratory characteristics of patients with pneumonia by SARS-CoV-2 coronavirus according to the measured levels of circulating soluble urokinase plasminogen activator receptor (suPAR)**

	suPAR < 6 ng/ml (n=20)	suPAR ≥ 6 ng/ml (n=20)	p-value
Age (years, mean ± SD) #	46.25 ± 17.63	68.30 ± 9.27	6 x 10 <sup>-5</sup> #
Male gender (n, %)	13 (65.0)	13 (65.0)	1.000 <sup>□</sup>
CCI (mean ± SD) #	3.56 ± 1.62	5.13 ± 0.99	0.022 <sup>#</sup>
APACHE II score (mean ± SD) #	7.28 ± 3.43	6.69 ± 5.25	0.953 <sup>#</sup>
SOFA (mean ± SD) #	0.86 ± 1.07	2.61 ± 1.20	0.004 <sup>#</sup>
ARDS (n, %)	0 (0.0)	6 (30)	3 x 10 <sup>-6</sup> <sup>□</sup>
<b>Main comorbidities (n, %)</b>			
Type 2 diabetes mellitus	1 (5.0)	4 (20.0)	0.342 <sup>□</sup>
Congestive heart failure	0 (0)	1 (5.0)	0.500 <sup>□</sup>
Coronary heart disease	1 (5.0)	3 (15.0)	0.658 <sup>□</sup>
COPD	0 (0)	1 (5.0)	0.506 <sup>□</sup>
<b>Laboratory values (mean ± SD)</b>			
White blood cells (mm <sup>3</sup> )	6007.14 ± 1500.55	7578.88 ± 3201.64	0.220 <sup>#</sup>
Absolute neutrophil counts (mm <sup>3</sup> )	3573.30 ± 1723.14	5833.80 ± 2988.62	0.055 <sup>#</sup>
Absolute lymphocyte counts (mm <sup>3</sup> )	2233.86 ± 1872.39	1203.26 ± 614.70	0.198 <sup>#</sup>
Platelets (x 10 <sup>3</sup> , mm <sup>3</sup> )	261.8 ± 133.8	212.1 ± 68.2	0.574 <sup>#</sup>
C-reactive protein (mg/l)	35.69 ± 53.43	89.19 ± 82.45	0.083 <sup>#</sup>
Fibrinogen (mg/dl)	352.00 ± 59.24	612.22 ± 187.67	0.003 <sup>#</sup>
Ferritin (ng/ml)	283.41 ± 244.73	882.90 ± 595.75	0.024 <sup>#</sup>
Procalcitonin (ng/ml)	0.06 ± 0.05	0.36 ± 0.36	0.133 <sup>#</sup>
D-dimers (ng/ml)	421.67 ± 324.10	1407.79 ± 3251.55	0.207 <sup>#</sup>
AST (U/l)	22.57 ± 6.68	46.44 ± 29.49	0.041 <sup>#</sup>
ALT (U/l)	27.14 ± 14.37	38.67 ± 27.78	0.458 <sup>#</sup>
Creatinine (mg/dl)	0.92 ± 0.27	0.97 ± 0.34	0.883 <sup>#</sup>
Total bilirubin (mg/dl)	0.259 ± 0.11	1.54 ± 2.06	0.001 <sup>#</sup>

**Abbreviations:** SD: standard deviation; APACHE: acute physiology and chronic health evaluation; CCI: Charlson's comorbidity index; SOFA: sequential organ failure; ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; AST: aspartate aminotransferase; ALT: alanine aminotransferase.

<sup>□</sup>Comparison by Fischer exact test; <sup>#</sup>Comparison by the Mann-Whitney U test.

478

479

480 **FIGURE LEGENDS**

481 **Figure 1 Calprotectin is increased in patients with ARDS due to COVID-19**

482 A-B) Concentrations of calprotectin (S100A8/A9) and high mobility group box 1  
483 (HMGB1) were measured in the plasma from healthy volunteers; from patients with  
484 COVID- 19 who did not develop ARDS during follow-up on the day of hospital  
485 admission; and from patients with ARDS by COVID- 19 on the first day of ARDS.  
486 Comparison by the Mann Whitney U test; ns non- significant;  $\square$   $p < 0.05$ ;  $\square\square$   $p < 0.01$ ;  $\square\square\square$   
487  $p < 0.001$ ;  $\square\square\square\square$ ;  $p < 0.0001$ .  
488 Panels C and D) suPAR was measured in 40 patients screened for participation in the  
489 SAVE trial (3). None of the patients with suPAR less than 6 ng/ml developed acute  
490 respiratory distress syndrome (ARDS), whereas 6 patients (30%) with suPAR 6 ng/ml or  
491 more developed ARDS.  
492 C) Concentrations of calprotectin in 20 patients with suPAR less than 6 ng/ml and in 20  
493 patients with suPAR 6 ng/ml or more. Comparison by the Mann Whitney U test;  $\square$   $p <$   
494 0.05.  
495 D) Correlation of levels of suPAR with plasma calprotectin on day of admission  
496 Spearman rank correlation coefficients ( $r_s$ ), interpolation lines and p- values are  
497 provided.

498

499

500 **Figure 2 A COVID- like animal model of compartmentalized hyperinflammation**

501 C57Bl6 mice were injected intravenously (i.v.) with plasma of healthy volunteers or  
502 patients with ARDS due to COVID-19 for three consecutive days. Mice were sacrificed  
503 on day 4. Tissue concentrations of A) tumor necrosis factor alpha (TNF $\alpha$ ); B) Interleukin  
504 (IL)-6; C) Interferon gamma (IFN $\gamma$ ) and D) myeloperoxidase (MPO) activity were

505 determined. Comparison by the Mann Whitney U test; ns non-significant;  $\square$   $p < 0.05$ ;  $\square\square$   
506  $p < 0.01$ ;  $\square\square\square\square$   $p < 0.0001$ .

507 E) C57Bl6 mice were injected intravenously (i.v.) with plasma of healthy volunteers or  
508 patients with ARDS due to COVID-19 for three consecutive days. On day 4 mice were  
509 challenged intraperitoneally (i.p.) with *E. coli* or *A. baumannii*. Survival comparison by  
510 the log-rank test and the respective p- value are provided.

511

512

513 **Figure 3 IL-1 inhibition attenuates the compartmentalized hyperinflammation in a**  
514 **COVID-like murine model**

515 In a COVID- like infection model, C57Bl6 mice were challenged intravenously (i.v.) with  
516 plasma of healthy volunteers or patients with ARDS due to COVID-19 for three  
517 consecutive days. In separate experiments, on each day of plasma challenge, mice  
518 were treated with Anakinra, which inhibits human and murine IL-1, or vehicle. Mice were  
519 sacrificed on day 4. A-C) Tumor necrosis factor alpha (TNF $\alpha$ ); D-E) Interleukin (IL) -6; F)  
520 Interferon gamma (IFN $\gamma$ ) and G-I) myeloperoxidase (MPO) activity was determined in  
521 tissues. Comparison by the Mann Whitney U test; ns non-significant;  $\square$   $p < 0.05$ ;  $\square\square$   $p <$   
522 0.01.

523

524

525 **Figure 4 Murine IL-1 $\alpha$  drives the hyperinflammation caused by SARS-CoV-2**

526 In a COVID- like infection model, C57Bl6 mice were challenged intravenously (i.v.) with  
527 plasma of patients with ARDS due to COVID-19 for three consecutive days. In separate  
528 experiments, on each day of plasma challenge, mice were treated with Flo1-2a anti-  
529 murine IL-1 $\alpha$  antibody or XB2001 human IL- 1 $\alpha$  antibody or murine isotype control



530 for Flo1-2a. Mice were sacrificed on day 4. A-C) Tumor necrosis factor alpha (TNF $\alpha$ );  
531 D-E) Interleukin (IL) -6; F) Interferon gamma (IFN $\gamma$ ) and G-I) myeloperoxidase (MPO)  
532 activity was determined in tissues. Comparison by the Mann Whitney U test; ns non-  
533 significant;  $\square$  p< 0.05;  $\square\square$  p< 0.01;  $\square\square\square$  p< 0.001.

534

535

### 536 **Figure 5 IL-1 inhibition primes Th1 responses in COVID-19**


537 A-C) In a COVID- like infection model, C57Bl6 mice were treated intravenously (i.v.) with  
538 plasma of healthy volunteers or patients with ARDS due to COVID-19 for three  
539 consecutive days. Mice were sacrificed on day 4. Splenocytes were isolated and  
540 incubated with heat killed *C. albicans* for the production of interferon-gamma (IFN $\gamma$ ),  
541 tumour necrosis factor-alpha (TNF $\alpha$ ) and interleukin (IL)-6.

542 D-F) In a COVID- like infection model, C57Bl6 mice were treated intravenously (i.v.) with  
543 plasma of patients with ARDS due to COVID-19 with or without treatment with the IL-1  
544 receptor inhibitor Anakinra for three consecutive days.


545 Mice were sacrificed on day 4. Splenocytes were isolated and incubated with heat killed  
546 *C. albicans* for the production of IFN $\gamma$ , TNF $\alpha$  and IL-6. Comparison by the Mann  
547 Whitney U test; ns non-significant;  $\square$  p< 0.05;  $\square\square$  p< 0.01.

548


A.




B.









C.




D.











A.


IFN $\gamma$ : Healthy vs COVID-19

B.


TNF $\alpha$ : Healthy vs COVID-19

C.


IL-6: Healthy vs COVID-19



D.

IFN $\gamma$ : Anakinra

E.

TNF $\alpha$ : Anakinra

F.

IL-6: Anakinra

